| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 952 | 778 | 800 | 811 | 1,223 | 1,029 | 989 | 1,086 | 974 | 986 | 1,025 | 1,098 | 1,242 | 1,193 | 1,564 | 1,585 | 1,557 | 1,483 | 1,673 | 1,784 | 1,621 | 1,712 | 1,765 | 1,885 | 2,060 | 1,808 | 1,945 | 2,223 | 2,476 | 2,217 | 2,384 | 3,020 | 3,929 | 3,516 | 3,551 | 4,135 | 3,912 | 4,543 | 3,604 | 3,826 | 4,415 |
| Expenses | 653 | 606 | 727 | 615 | 740 | 719 | 706 | 762 | 738 | 735 | 786 | 836 | 937 | 886 | 982 | 1,160 | 1,137 | 1,029 | 1,174 | 1,307 | 1,247 | 1,284 | 1,363 | 1,459 | 1,476 | 1,427 | 1,515 | 1,733 | 1,911 | 1,783 | 1,894 | 2,624 | 2,820 | 2,741 | 2,769 | 3,051 | 3,013 | 2,813 | 2,905 | 3,070 | 3,339 |
| EBITDA | 300 | 172 | 73 | 196 | 483 | 309 | 283 | 324 | 236 | 250 | 239 | 262 | 306 | 307 | 582 | 425 | 420 | 454 | 499 | 477 | 373 | 428 | 402 | 427 | 584 | 380 | 430 | 489 | 565 | 434 | 490 | 396 | 1,109 | 775 | 782 | 1,084 | 900 | 1,730 | 699 | 756 | 1,077 |
| Operating Profit % | 21 % | 20 % | 6 % | 22 % | 21 % | 27 % | 25 % | 27 % | 20 % | 21 % | 19 % | 21 % | 20 % | 21 % | 26 % | 25 % | 26 % | 29 % | 25 % | 25 % | 20 % | 24 % | 22 % | 21 % | 20 % | 19 % | 18 % | 20 % | 21 % | 17 % | 18 % | 11 % | 25 % | 20 % | 18 % | 14 % | 22 % | 17 % | 18 % | 19 % | 23 % |
| Depreciation | 59 | 59 | 61 | 64 | 65 | 66 | 68 | 70 | 73 | 99 | 94 | 97 | 95 | 99 | 112 | 117 | 120 | 124 | 132 | 144 | 152 | 167 | 178 | 186 | 184 | 195 | 202 | 206 | 212 | 218 | 231 | 301 | 364 | 358 | 389 | 415 | 407 | 405 | 420 | 425 | 436 |
| Interest | 0 | 4 | 3 | 2 | 21 | 6 | 7 | 9 | 5 | 16 | 14 | 15 | 17 | 18 | 19 | 19 | 16 | 17 | 14 | 18 | 17 | 13 | 7 | 5 | 34 | 20 | 23 | 15 | 11 | 20 | 30 | 120 | 249 | 233 | 248 | 267 | 227 | 236 | 226 | 223 | 212 |
| Profit Before Tax | 249 | 165 | 20 | 141 | 409 | 238 | 208 | 245 | 159 | 135 | 132 | 150 | 193 | 190 | 451 | 289 | 284 | 313 | 354 | 315 | 204 | 249 | 218 | 236 | 366 | 166 | 206 | 269 | 343 | 197 | 229 | -26 | 497 | 184 | 214 | 808 | 319 | 1,146 | 98 | 156 | 487 |
| Tax | 32 | 34 | 18 | 19 | 55 | 55 | 42 | 54 | 10 | 38 | 43 | 36 | 41 | 52 | 73 | 46 | 41 | 85 | 100 | 85 | 45 | 81 | 22 | 49 | 69 | 57 | 46 | 49 | 59 | 30 | 147 | -5 | 82 | 35 | 42 | 55 | 96 | 284 | 71 | 75 | 27 |
| Net Profit | 217 | 131 | 2 | 122 | 354 | 182 | 167 | 191 | 148 | 98 | 89 | 114 | 153 | 138 | 378 | 243 | 243 | 228 | 254 | 230 | 159 | 168 | 195 | 187 | 296 | 108 | 160 | 220 | 284 | 167 | 82 | -21 | 415 | 149 | 173 | 753 | 223 | 862 | 27 | 81 | 459 |
| EPS in ₹ | 10.08 | 6.31 | -0.54 | 5.30 | 16.97 | 8.49 | 7.48 | 8.72 | 6.49 | 1.38 | 1.17 | 1.56 | 2.21 | 1.02 | 3.00 | 3.67 | 3.61 | 1.74 | 1.82 | 1.71 | 1.04 | 1.26 | 1.39 | 1.42 | 2.13 | 0.71 | 1.16 | 1.57 | 2.00 | 1.21 | 0.39 | -0.35 | 2.62 | 0.85 | 1.05 | 5.52 | 1.13 | 5.51 | -0.13 | 0.21 | 2.88 |
Biocon
373.85
+4.50
(1.22%)
There are 2 new updates from the company16 hours ago
View
Market Cap
49,982.39 Cr
EPS
8.46
PE Ratio
52.48
Dividend Yield
0.30 %
Industry
Healthcare52 Week High
404.70
52 Week Low
291.00
PB Ratio
1.89
Debt to Equity
0.91
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from16 analysts
Company News
View All News
Biocon to Review Q1 Results on August 715 hours ago
Biocon has announced that it will review its first quarter results on August 7. The company has scheduled a meeting to discuss and analyze its financial performance for the latest quarter.
Biocon Biologics has obtained approval from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for two denosumab biosimilars, Vevzuo and Evfaxy. These biosimilars are versions of a medication used to treat various bone-related conditions.
Biocon Biologics: EU Approves Two Denosumab Biosimilars5 days ago
Biocon Biologics, a subsidiary of Biocon Ltd., received European Commission marketing authorization for two Denosumab biosimilars, Vevzuo and Evfraxy. Vevzuo is for bone complications in advanced cancer, while Evfraxy treats osteoporosis in specific patient groups. This approval follows a positive CHMP opinion in April 2025.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,674.70 | #1 4,01,816.63 | 35.03 | #1 54,729.00 | 12.06 | #1 10,980 | -18.99 | 48.33 | |
6,976.50 | 1,85,204.15 | 83.99 | 9,360.00 | 0.89 | 2,117 | 23.05 | 68.54 | |
1,497.40 | 1,20,946.17 | 23.36 | 28,409.50 | 7.12 | 5,291 | 30.28 | 54.26 | |
3,328.00 | 1,12,634.64 | 58.72 | 11,539.40 | 11.59 | 1,911 | 10.91 | 62.08 | |
1,281.20 | 1,06,925.25 | 19.31 | 33,741.20 | 12.36 | 5,725 | 21.14 | 54.13 | |
2,442.60 | 1,00,813.12 | 50.50 | 12,207.40 | 19.57 | 1,925 | -10.91 | 59.65 | |
976.70 | 98,278.87 | 21.18 | 22,573.80 | 13.82 | 3,977 | -0.19 | 69.99 | |
1,955.70 | 89,315.93 | 26.75 | 22,192.10 | #1 19.94 | 3,024 | #1 112.49 | 53.08 | |
34,090.00 | 72,438.87 | 51.39 | 6,409.15 | 10.80 | 1,417 | 27.83 | 64.97 | |
1,150.50 | 66,821.23 | #1 19.29 | 31,378.10 | 17.55 | 3,366 | -0.50 | 63.70 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
35.25 %
Net Income Growth
101.84 %
Cash Flow Change
59.45 %
ROE
79.37 %
ROCE
103.31 %
EBITDA Margin (Avg.)
6.64 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 | 58,797 |
| Fixed Assets | 1,630 | 1,749 | 3,626 | 3,700 | 4,471 | 5,971 | 6,364 | 6,569 | 29,468 | 30,644 | 23,686 |
| Current Assets | 2,563 | 3,971 | 4,048 | 4,149 | 4,889 | 5,325 | 7,600 | 8,382 | 12,334 | 15,179 | 16,286 |
| Capital Work in Progress | 1,677 | 2,240 | 839 | 1,303 | 1,899 | 2,196 | 2,800 | 4,110 | 7,317 | 7,993 | 4,102 |
| Investments | 230 | 901 | 1,253 | 675 | 1,012 | 966 | 1,952 | 1,588 | 2,069 | 1,000 | 4,931 |
| Other Assets | 2,839 | 3,569 | 3,676 | 4,312 | 4,811 | 5,311 | 7,406 | 8,127 | 13,189 | 16,434 | 0 |
| Total Liabilities | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 | 58,797 |
| Current Liabilities | 1,555 | 1,666 | 1,678 | 2,141 | 3,039 | 4,008 | 4,210 | 3,828 | 8,511 | 15,359 | 14,334 |
| Non Current Liabilities | 1,378 | 2,493 | 2,502 | 2,200 | 2,447 | 3,053 | 5,805 | 7,096 | 21,043 | 15,437 | 16,751 |
| Total Equity | 3,443 | 4,300 | 5,214 | 5,649 | 6,707 | 7,383 | 8,508 | 9,470 | 22,489 | 25,275 | 21,644 |
| Reserve & Surplus | 3,171 | 3,992 | 4,738 | 4,881 | 5,798 | 6,106 | 7,027 | 7,832 | 17,267 | 19,183 | 21,044 |
| Share Capital | 100 | 100 | 100 | 300 | 300 | 600 | 600 | 600 | 600 | 600 | 600 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -94 | 300 | -47 | -261 | 210 | 165 | 72 | -243 | 641 | -380 |
| Investing Activities | -491 | -1,138 | -510 | -684 | -703 | -1,505 | -3,651 | -1,662 | -14,260 | -1,002 |
| Operating Activities | 211 | 371 | 640 | 662 | 1,155 | 1,283 | 1,160 | 1,177 | 1,853 | 2,954 |
| Financing Activities | 186 | 1,068 | -178 | -240 | -242 | 388 | 2,564 | 242 | 13,049 | -2,333 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 60.67 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 54.45 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 7.96 % | 6.55 % | 5.63 % | 5.90 % | 5.93 % | 5.66 % | 5.66 % | 7.00 % |
| DIIs | 6.65 % | 6.89 % | 6.87 % | 6.83 % | 7.79 % | 7.30 % | 7.76 % | 8.63 % | 11.90 % | 12.56 % | 14.08 % | 14.51 % | 13.68 % | 14.30 % | 14.44 % | 15.37 % | 15.72 % | 21.45 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 10.89 % | 11.03 % | 11.49 % | 11.37 % | 10.87 % | 10.72 % | 12.07 % | 12.46 % | 13.21 % | 13.34 % | 13.61 % | 14.47 % | 15.53 % | 14.63 % | 14.57 % | 14.07 % | 13.63 % | 13.08 % |
| Others | 21.79 % | 21.44 % | 21.00 % | 21.16 % | 20.70 % | 21.35 % | 19.54 % | 18.27 % | 14.26 % | 13.46 % | 3.70 % | 3.83 % | 4.52 % | 4.53 % | 4.42 % | 4.27 % | 4.34 % | 4.00 % |
| No of Share Holders | 0 | 3,11,349 | 3,38,815 | 3,63,447 | 3,64,502 | 3,47,911 | 3,41,016 | 3,69,816 | 4,11,086 | 4,12,441 | 4,15,046 | 4,34,339 | 4,70,261 | 4,43,513 | 4,39,503 | 4,27,705 | 4,24,297 | 4,30,217 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3 | 1 | 1 | 0.00 | 0.00 | 0.5 | 1.5 | 0.5 | 0.00 |
| Dividend Yield (%) | 0.00 | 1.01 | 0.33 | 0.37 | 0.00 | 0.00 | 0.25 | 0.57 | 0.15 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 08 Aug 2025 |  Annual General Meeting | NA | 08 Aug 2025 | 334.60 | 369.35 |
| 04 Jul 2025 |  Dividend | ₹ 0.50 /share | 04 Jul 2025 | 334.60 | 380.05 |
| 08 May 2025 |  Quarterly Result Announcement | NA | 08 May 2025 | 342.25 | 334.60 |
| 30 Jan 2025 | Quarterly Result Announcement | NA | 30 Jan 2025 | 369.25 | 357.15 |
| 30 Oct 2024 | Quarterly Result Announcement | NA | 30 Oct 2024 | 356.95 | 320.70 |
| 09 Aug 2024 | Annual General Meeting | NA | 09 Aug 2024 | 305.90 | 336.95 |
| 05 Jul 2024 | Dividend | ₹ 0.50 /share | 05 Jul 2024 | 305.90 | 370.20 |
| 07 Jul 2023 | Dividend | ₹ 1.50 /share | 07 Jul 2023 | 242.25 | 254.00 |
| 01 Jul 2022 | Dividend | ₹ 0.50 /share | 30 Jun 2022 | 376.75 | 311.65 |
| 13 Jun 2019 |  Bonus | 1:1 | 12 Jun 2019 | 270.50 | 256.40 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
16 hours ago
16 hours agoBoard Meeting Intimation for Board Meeting Intimation To Approve And Take On Record The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 202516 hours ago
16 hours agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 27, 2025
Jun 27, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Disclosure Under Regulation 30 Of The SEBI Listing RegulationsJun 26, 2025
Jun 26, 2025Board Meeting Outcome for Outcome Of Board MeetingJun 26, 2025
Jun 26, 2025Communication To The Shareholders W.R.T. TDS On Final DividendJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 24, 2025
Jun 24, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 20, 2025
Jun 20, 2025Announcement under Regulation 30 (LODR)-Qualified Institutional PlacementJun 20, 2025
Jun 20, 2025Qualified Institutions Placement - Approval And Adoption Of The Placement Document Dated June 19 2025Jun 19, 2025
Jun 19, 2025Qualified Institutions PlacementJun 19, 2025
Jun 19, 2025Credit RatingJun 18, 2025
Jun 18, 2025Qualified Institutions Placement Of Equity SharesJun 16, 2025
Jun 16, 2025Intimation Of The Approval Of The Audited Consolidated Financial Statements For The Financial Year March 31 2025Jun 16, 2025
Jun 16, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 09, 2025
Jun 09, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJun 04, 2025
Jun 04, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJun 04, 2025
Jun 04, 2025Press ReleaseJun 02, 2025
Jun 02, 2025Reminder Letter To Holders Of Physical Securities For Furnishing Of KYC DetailsMay 27, 2025
May 27, 2025Company StatementMay 25, 2025
May 25, 2025Company StatementMay 22, 2025
May 22, 2025Company StatementMay 21, 2025
May 21, 2025Transcript Of Earnings Call Q4 FY25May 15, 2025
May 15, 2025Notification To Stock ExchangeMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 14, 2025
May 14, 2025Reminder Letter To Shareholders To Claim Unclaimed DividendsMay 13, 2025
May 13, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 12, 2025
May 12, 2025Investor PresentationMay 12, 2025
May 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 10, 2025
May 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 09, 2025
May 09, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 09, 2025
May 09, 2025Fixation Of Record Date For DividendMay 08, 2025
May 08, 2025Corporate Action-Board approves DividendMay 08, 2025
May 08, 2025Board Meeting Outcome for Financial Results For Quarter And Year Ended March 31 2025May 08, 2025
May 08, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 08, 2025
May 08, 2025Financial Results For The Quarter And Year Ended March 31 2025May 08, 2025
May 08, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 06, 2025
May 06, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotMay 05, 2025
May 05, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 05, 2025
May 05, 2025Intimation Of Record Date For Commercial PapersApr 30, 2025
Apr 30, 2025Redemption Of Commercial PapersApr 29, 2025
Apr 29, 2025 Company Statement Dated April 26 2025Apr 26, 2025
Apr 26, 2025Board Meeting Outcome for Outcome Of Board MeetingApr 23, 2025
Apr 23, 2025Issue Of Commercial PapersApr 22, 2025
Apr 22, 2025Board Meeting Intimation for To Consider And Approve The Proposal For Raising Of Funds.Apr 20, 2025
Apr 20, 2025Technical Indicators
RSI(14)
Neutral 62.43
ATR(14)
Less Volatile 9.09
STOCH(9,6)
Overbought 85.08
STOCH RSI(14)
Neutral 65.80
MACD(12,26)
Bullish 1.66
ADX(14)
Strong Trend 26.31
UO(9)
Bearish 61.95
ROC(12)
Uptrend And Accelerating 5.12
WillR(14)
Neutral -32.44
Mutual Fund Holdings
SBI Contra Direct Plan-Growth 
Kotak Large & Midcap Fund Direct-Growth 
Nippon India Focused Fund Direct-Growth 
HSBC Midcap Fund Direct-Growth 
Mirae Asset Large Cap Fund Direct- Growth 
ICICI Prudential Multi Asset Fund Direct-Growth 
Bandhan Large & Mid Cap Fund Direct-Growth 
Mahindra Manulife Mid Cap Fund Direct - Growth 
Invesco India Arbitrage Fund Direct-Growth 
HDFC Large and Mid Cap Fund Direct- Growth About Biocon
Biocon Limited is India's largest fully-integrated biopharmaceutical company, focusing on biotechnology products and research services. Founded in 1978, Biocon specializes in treating diabetes, cancer, and autoimmune diseases. The company develops and commercializes novel biologics, biosimilars, complex small molecule APIs, and generic formulations for global markets. Biocon's product portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, and oncology treatments. The company operates manufacturing facilities in Bangalore, Hyderabad, and Visakhapatnam, utilizing various technology platforms such as microbial fermentation, chromatographic purification, chemical synthesis, and peptide synthesis. Biocon has expanded its global presence through strategic partnerships and has launched several biosimilar and generic products in international markets, including the United States, Europe, and emerging economies.
Listing Date
07 Apr, 2004(21 Years,
2 days)
Website
Chairperson NameKiran Mazumdar Shaw
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
